ACIP

How the Advisory Committee on Immunization Practices evaluates evidence and develops vaccine recommendations.

The Advisory Committee on Immunization Practices (ACIP) is a group of medical and public health experts that provides advice to the Centers for Disease Control and Prevention (CDC) on the use of vaccines in the United States. ACIP's recommendations form the basis of the national immunization schedule and influence insurance coverage requirements.

Who Serves on ACIP

ACIP consists of 15 voting members selected for their expertise in vaccinology, immunology, pediatrics, internal medicine, nursing, family medicine, virology, public health, and consumer perspectives.

Members include:

  • Experts in vaccines and immunology (academic researchers, clinicians)
  • Representatives from organizations like the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the Infectious Diseases Society of America (IDSA)
  • Consumer representatives (public members without industry ties)
  • Ex-officio members from FDA, NIH, HHS, and the Indian Health Service

Members serve 4-year terms and meet three times annually (more frequently during public health emergencies).

Conflict of Interest Rules

ACIP has strict conflict-of-interest rules. Members must disclose all financial relationships with vaccine manufacturers. Those with significant conflicts are recused from relevant votes. This ensures recommendations are based on evidence, not industry influence.

How Evidence Is Evaluated

ACIP uses the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework to systematically assess vaccine evidence:

  • Type of evidence (randomized trials vs. observational studies)
  • Quality of evidence (risk of bias, consistency, directness)
  • Benefits vs. harms (balance of advantages and risks)
  • Values and preferences (patient and provider preferences)
  • Resource use (cost-effectiveness considerations)

The Voting Process

  1. CDC presents disease burden and vaccine data
  2. Work Group presents evidence review and recommendation options
  3. Public comments are heard
  4. Committee discusses questions and concerns
  5. Vote taken on each recommendation category
  6. Recommendations published in MMWR

From Recommendation to Policy

ACIP recommendations become policy when:

  • Recommendations are published in MMWR (Morbidity and Mortality Weekly Report)
  • CDC adopts recommendations as official policy
  • Recommendations are incorporated into the Immunization Schedule
  • Insurance coverage is required under the Affordable Care Act

2026 Policy Changes: Process and Public Debate

In early 2026, the federal government implemented changes to the process by which vaccine recommendations reach the public. This section documents the chronology and the institutional responses.

What Changed

Executive action directed HHS to streamline the vaccine recommendation process by consolidating certain review functions that had previously been distributed across ACIP, the CDC, and HHS. Under the revised process, HHS exercises direct authority over the final publication of vaccine recommendations, reducing the number of intermediate review stages between ACIP's vote and official policy adoption.

Executive Authority vs. Committee Process

The restructuring reflects a tension between two governance models. The executive authority model prioritizes efficiency, unified accountability, and the ability to respond rapidly to emerging public health needs. The committee process model prioritizes deliberation, multi-stakeholder input, transparency through public meetings, and the established evidence-review sequence that has governed U.S. vaccine recommendations for decades.

Supporters of the changes argue that consolidating authority allows faster policy responses and clearer lines of accountability. They note that ACIP's advisory role is preserved — the committee continues to evaluate evidence and vote on recommendations — and that the changes primarily affect the administrative pathway between committee recommendations and published policy.

Institutional Responses

Professional medical organizations including the American Academy of Pediatrics (AAP) and the Infectious Diseases Society of America (IDSA) have documented concerns regarding the departure from the established evidence-review sequence. Their stated concern is that reducing independent review stages could weaken the scientific rigor that has historically underpinned U.S. vaccine policy, even if the committee's formal advisory role remains intact.

Other institutional voices, including some within HHS, have argued that the prior multi-stage process created unnecessary delays and that the revised structure maintains all substantive safety and efficacy review while removing procedural redundancy.

This policy area remains in active development. Readers should consult primary sources including the Federal Register, CDC.gov, and official HHS communications for the most current information.

Sources & Citations